Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-11-11

Clinical Trial Update: Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating maintenance sorafenib in patients with small cell lung cancer after response to induction chemotherapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Small Cell Lung Cancer | Phase 2 | Status: TERMINATED